Investor and Analyst R&D Forum

Developing respiratory drugs to improve health and quality of life

Verona Pharma

October 12, 2018, New York City

(AIM: VRP) (NASDAQ: VRNA)
www.veronapharma.com

Forward-Looking Statements

Verona Pharma

This presentation contains "forward-looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking statements include information concerning the initiation, timing, progress and results of clinical trials of the Company's product candidate, the timing or likelihood of regulatory filings and approvals for any of its product candidates, and estimates regarding the Company's expenses, future revenues and future capital requirements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include those under "Risk Factors" in the Company's annual report on Form 20-F filed with the Securities and Exchange Commission (the "SEC") on February 27, 2018, and in its other reports filed with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this presentation. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this presentation, or to conform any of the forward-looking statements to actual results or to changes in its expectations.

This presentation also contains estimates, projections and other information concerning the Company's business and the markets for the Company's product candidate, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources.

Verona Pharma

Welcome

Jan-Anders Karlsson, CEO, Verona Pharma

We are **a clinical stage** biopharma focused on developing & commercializing **innovative therapeutics** for treatment of **respiratory diseases** with significant **unmet need**

Demonstrate Urgent Unmet Medical Need in COPD & Highlight RPL554 Development Program

Verona Pharma

Time	Details
11:15 am – 11:30 am	**Welcome** (*Jan-Anders Karlsson, CEO, Verona Pharma*)
11:30 am – 12:00 pm	**The Patient Perspective, COPD Foundation** (*John Linnell, Patient; Sara Latham, COO, COPD Foundation*)
12:00 pm – 1:10 pm	**Clinical Expert Perspective** • *COPD treatment challenges/ unmet need [Bob Wise, M.D. 20 min]* • *COPD Treatment Pipeline inc. RPL554 [Gerard Criner, M.D. 20 min]* • *RPL554 Clinical Results/ Ongoing trials [Dave Singh, M.D. 30 min]*
1:10 pm – 1:45 pm	**Speaker Panel Q&A**
1:45 pm – 2:00 pm	**Close** (*Jan-Anders Karlsson*)

RPL554 First-in-Class Candidate: Bronchodilator and Anti-inflammatory in a Single Compound

Verona Pharma

Inhaled dual inhibitor of enzymes PDE3 and PDE4	RPL554	First novel class of bronchodilator in decades

- Developing nebulized RPL554 for **COPD**
- Advancing DPI and MDI formulations for **COPD** into clinic
- Opportunities in other respiratory indications:
  Cystic Fibrosis, Asthma

COPD, Chronic Obstructive Pulmonary Disease; DPI, Dry Powder Inhaler; MDI, Metered Dose Inhalers

Despite Advances in COPD Management, Many Patients Remain Uncontrolled and Symptomatic

Verona Pharma

- **Third leading cause of death in US[1]**
- **Up to 16 million US patients diagnosed with COPD[2]**
- **Unmet Need For New Treatments**
  - Add-on to current therapies
  - Improve lung function
  - Improve symptoms (esp. breathlessness)
  - Prevent exacerbations

Consequences of severe exacerbations



1. National Center for Health Statistics. Report No.: 2016-1232.. 2 Wheaton AG et al. MMWR Morb Mortal Wkly Rep. 2015:64 (11):290–295. 3. Ford, E, et al. Chest 144.1 (2013): 284-305. 4. Ford, E. Chest 147.4 (2015): 989-998. . 5. Kinnunen, T. et al. Respiratory medicine 101.2 (2007): 294-299. 6. COPD Death Rates in the US. https://www.cdc.gov/copd/data.html

RPL554: Uniquely Placed as Bronchodilator and Anti-inflammatory with Novel Mode of Action

Large numbers of uncontrolled and symptomatic COPD patients

Verona Pharma



Sources: Q2 2017 US COPD patient database & physician survey research, IQVIA MIDAS Sales, Mullerova H et al. American Journal of Respiratory and Critical Care Medicine 2017; Vestbo J, et al. Lancet 2017; Bateman et al. Eur Respir J 2013; Vogelmeier et al. Lancet Respir Med. 2013; Mahler et al. Eur Respir J 2013

RPL554: Robust Product Pipeline Addressing Patients with Moderate to Severe COPD

Verona Pharma

Indication	Delivery	Pre-Clinical	Phase 1	Phase 2	Phase 3
COPD Maintenance	Nebulizer 	→	→	→	
COPD Acute (Hospital)		→	→	→	
Cystic Fibrosis		→	→	→	
COPD Maintenance	MDI 	→			
COPD Maintenance	DPI 	→			

Compelling data in COPD and CF
Additional opportunities in novel inhaler formulations and potentially in asthma

DPI and MDI Formulations of RPL554 - Potential to Expand Commercial Opportunity in COPD

- Inhaler usage for maintenance therapy (U.S. estimates)
  - ~90% of 3.7 million mild/moderate COPD patients
  - ~80% of 2.7 million severe/very severe COPD patients
- Next steps in DPI and MDI formulation development
  - DPI clinical trials planned to start 4Q 2018 – topline data expected 1H 2019
  - MDI clinical trials planned to start 1H 2019 – topline data expected 2H 2019
- Potential to broaden use in other indications, such as asthma
- Available for out-licensing

Sources: combined analysis of Q2 '17 IQVIA analytics & Q1 '18 Verona US Physician Market Research

Nebulized RPL554: Effective and Well Tolerated in 12 Clinical Trials with >730 Subjects

Verona Pharma

Trial	Program	# Subjects	Duration	Status
Phase 1/2	SAD MAD study with suspension formulation	**112**	Single dose & 5 days	Completed Sept 2015
Phase 2a	Dose ranging in asthma	**29**	Single dose	Completed March 2016
Phase 2a	Add-on to each of albuterol or ipratropium	**30**	Single dose	Completed May 2016
Phase 2a	Add-on to tiotropium (Spiriva®)	**30**	3 days	Completed Sept 2017
Phase 1	PK trial, US FDA new IND	**12**	Single dose	Completed Sept 2017
Phase 2b	Maintenance treatment	**403**	4 weeks	Completed March 2018
Phase 2	Add-on to LAMA/LABA (Stiolto)	**~75**	3 days	Started July 2018

Nebulized RPL554: Towards Phase 3 as Maintenance Treatment in COPD

Verona Pharma

- **Pivotal trials in moderate to severe/very severe and symptomatic COPD patients who prefer/accept nebulizer treatment**
- **Position RPL554 as "add-on" to "Standard-of-Care" treatment**
  - Add-on to current bronchodilator treatment
  - Targeting uncontrolled and symptomatic COPD patients
  - Twice daily nebulizer therapy
  - Positioning supported by quantitative market research
- **Potential endpoints: lung function (e.g. FEV_1), symptom improvement**
- **Focus on speed and cost in pivotal trials with nebulizer treatment**
  - Two trials, each with 3 to 6 months duration; collecting 12 months safety data
  - Pivotal trials to commence subsequent to End-of-Phase 2 (EOP2) meeting planned for 2H 2019

FEV_1, Forced expiratory volume in 1 second

Multiple Upcoming Inflection Points next 6 to 12 months

Verona Pharma

Clinical Development	Timing
Nebulized RPL554 as maintenance treatment of COPD	
Top-line data from Phase 2 RPL554 as add-on to LAMA/LABA w/wo ICS	1Q 2019
FDA: EOP2 meeting	2H 2019
⇨ Subsequently, advancing into Phase 3 trials	Late 2019
RPL554 DPI and MDI formulations	
DPI start of clinical Phase 2 trials	4Q 2018
Top-line data from Phase 2 DPI trials	1H 2019
MDI start of clinical Phase 2 trials	1H 2019
Estimated top-line data MDI Phase 2 trials	2H 2019

RPL554 – A Promising Novel Treatment For Patients with COPD:

Verona Pharma

Data collected to date indicates:

- ✓ RPL554 – unique PDE3/4 inhibitor with bronchodilator and anti-inflammatory effects, and well tolerated
- ✓ Improves symptoms in moderate to severe, symptomatic COPD patients on twice daily dosing
- ✓ Effective both as stand-alone drug and as add-on to standard COPD treatments
- ✓ Planning FDA End of phase 2 meeting 2H 2019
- ✓ Subsequently, advancing nebulized RPL554 into Phase 3 trials in uncontrolled and symptomatic patients despite using standard COPD medications

Agenda

Verona Pharma

Time	Details
11:15 am – 11:30 am	**Welcome** (Jan-Anders Karlsson, CEO, Verona Pharma)
11:30 am – 12:00 pm	**The Patient Perspective, COPD Foundation** (*John Linnell, Patient*; *Sara Latham, COO, COPD Foundation*)
12:00 pm – 1:10 pm	**Clinical Expert Perspective** • *COPD treatment challenges/ unmet need [Bob Wise, M.D. 20 min]* • *COPD Treatment Pipeline inc. RPL554 [Gerard Criner, M.D. 20 min]* • *RPL554 Clinical Results/ Ongoing trials [Dave Singh, M.D. 30 min]*
1:10 pm – 1:45 pm	**Speaker Panel Q&A**
1:45 pm – 2:00 pm	**Close** (Jan-Anders Karlsson)

Verona Pharma

Patient Perspectives

Symptoms & Disease Progression: How COPD Symptoms Impact Quality of Life

John Linnell

COPD Patient

Investor and Analyst R&D Forum
New York, NY

October 12, 2018

My name is John Linnell
From: Wisconsin
Role: COPD Foundation Wisconsin State Captain

How did I find out I had COPD?

How have I had to adjust my lifestyle to accommodate COPD?

My COPD Journey and Those Who Take it With Me







Emotional Challenges of COPD

- **Denial** – *I don't have COPD or emphysema. I was just fine until I got that last cold. This is just bronchitis.*
- **Fear** – *(Feeling it and fighting it) I can't let this get to me, because if I do, it just means I'm weak and giving in.*
- **Loneliness** – *I must be the only one who has this. If there are others, where are they?*
- **Confusion** – *Inhalers, nebulizers, oxygen…this is just too much to take in. I'm confused and overwhelmed and my breathing is out of control.*
- **Isolation** – *Nobody can possibly understand what it's like to be so short of breath.*
- **Despair** – *I can't do anything anymore and I'm of no use to anyone*

COPD Symptoms and Exacerbations



New Treatment Options are Critical for Those of Us Living with COPD






Take Action Today. Breathe Better Tomorrow.

COPD FOUNDATION

Verona Pharma

PATIENT PERSPECTIVES
Need For New Treatments

Sara Latham
EVP, Global Engagement, COO, COPD Foundation

COPD FOUNDATION
Take Action Today. Breathe Better Tomorrow.

Investor and Analyst R&D Forum

Friday, October 12, 2018
New York City, NY

Our Approach

COPD FOUNDATION

COPD IN 2018

- COPD is now the 3rd leading cause of death in US among chronic diseases
- Over 155,00 deaths per year
- 16 million Americans diagnosed
- Estimates suggest 12-15 million more undiagnosed
- 70% of COPD sufferers are in workforce
- COPD is now 2nd leading cause of disability in US
- Cost of care now over $50 billion dollars a year in both direct and indirect costs
- No new classes of treatment for COPD approved since 2011

COPD FOUNDATION

COPD in the United States



Behavioral Risk Factor Surveillance System (BRFSS)-Centers for Disease Control & Prevention: 2011-14

COPD FOUNDATION



COPD FOUNDATION



COPD FOUNDATION

COPD IS NOT JUST A SMOKER'S DISEASE



20-25% of people with COPD have never smoked

Environmental Tobacco

Age

Gender

Alpha-1

Genes

Cigarette Smoke

Fumes/ Gases

Occupational Dust

Nutrition

In/Outdoor Pollution

Socio-Economic Status

Pre-natal, Childhood Events, Asthma

COPD FOUNDATION

COPD IS COMPLEX



DATA FROM BRFSS-Centers for Disease Control & Prevention

COPD FOUNDATION

But Statistics Don't Tell the Whole Story






COPD FOUNDATION

A Growing Need – Evolution of COPD360social

The COPD Foundation has invested significant resources to build its technical infrastructure and as a result of a detailed SEO plan and strategic content development, on average www.copdfoundation.org receives upwards of 150,000 site visitors per month and 2.6 million visitors in 2017. Since its launch in November 2014, over 35,000 individuals have joined COPD360social.



Users	New Users	Sessions
883.94%	880.33%	861.53%
1,955,735 vs 198,765	1,913,122 vs 195,150	2,355,487 vs 244,972

COPD360social

IT'S OUR COMMUNITY ONLINE

COPD Foundation Website Total Visits by Year:

2013: 147,987
2014: 489,933
2015: 922,803
2016: 1,966,152
2017: 2,593,909

COPD360social Membership (launched November 19, 2014):

Caregivers: 2,597
Family/Friends: 4,519
Healthcare Professionals: 12,738
Patients: 15,344
Total Membership: 35,198

COPD FOUNDATION

June 2018 Survey Results – Respondent Profile

- More than half of respondents (58%) rate their health as fair or poor. Two respondents in three (62%) have lived with COPD for more than five years.
- Younger respondents (under 65) are more likely to report lower overall health status (69% rate fair/poor vs. 52% 65+).



Q7. How would you describe your overall health status? n=600



Q6. How many years has it been since you were initially diagnosed by a physician with COPD? n=600

Respondent Demographics









COPD FOUNDATION

We need to encourage and speed the development of novel therapies that meet the high unmet need in COPD and help get those treatments to the community – meaning approved, reimbursed and implemented in practice

COPD FOUNDATION


KIDS' FALL SERIES
189

Take Action Today. Breathe Better Tomorrow.

COPD FOUNDATION

Agenda

Verona Pharma

Time	Details
11:15 am – 11:30 am	**Welcome** (Jan-Anders Karlsson, CEO, Verona Pharma)
11:30 am – 12:00 pm	**The Patient Perspective, COPD Foundation** (*John Linnell, Patient; Sara Latham, COO, COPD Foundation*)
12:00 pm – 1:10 pm	**Clinical Expert Perspective** • *COPD treatment challenges/ unmet need [Bob Wise, M.D. 20 min]* • *COPD Treatment Pipeline inc. RPL554 [Gerard Criner, M.D. 20 min]* • *RPL554 Clinical Results/ Ongoing trials [Dave Singh, M.D. 30 min]*
1:10 pm – 1:45 pm	**Speaker Panel Q&A**
1:45 pm – 2:00 pm	**Close** (Jan-Anders Karlsson)

Verona Pharma

Clinical Expert Perspectives

COPD treatment challenges/ unmet need

Robert Wise

M.D., Director of Research and Professor, Division of Pulmonary and Critical Care Medicine at John Hopkins University

COPD causes considerable clinical and economic burden

- More than 16 million people diagnosed with COPD in US; millions more may not have been diagnosed[1]
- In a recent US survey, 83% of patients were classified as symptomatic (GOLD B or D)[2]
- COPD is the third most common medical cause of death in the USA[3]
- In 2010, the cost of COPD in the USA was projected to be approximately US$50 billion[2]
  - $20 billion in indirect costs
  - $30 billion in direct health care expenditures
- These costs can be expected to continue to rise with this progressive disease[3]
- Hospital stays account for the majority of these costs[3]

1. NHLBI COPD National Action Plan. Available at: https://www.nhlbi.nih.gov/health-topics/education-and-awareness/COPD-national-action-plancopd.html
2. Ding Int J COPD 2018
3. Guarascio AJ et al. Clinicoecon Outcomes Res 2013;5:235–245

Unmet needs in COPD

- Symptoms
- Impaired physical activity, airflow limitation
- Recurrent exacerbations
- Difficulty with handheld inhalers

Symptoms of COPD: breathlessness, cough, sputum

HEALTHY



COPD



Multiple symptoms of COPD have a real impact on patient well-being

SYMPTOMS[1–4]	IMPACT ON WELL-BEING[1–5]
Shortness of breath	Activity/exercise limitation
Cough	Anxiety and depression
Wheezing	Apprehension about future events
Chest tightness	Lack of confidence about steps to take action
Sputum production	Risk of increasing social isolation
Worse in morning	Loss of independence
Fatigue	

[1]GOLD. 2014; [2]O'Donnell DE. Eur Respir Rev 2006; [3]Rennard. Eur Respir J 2002; [4]Barnett M. J Clin Nurs 2005; [5]Cleland JA. Fam Pract 2007.

COPD, chronic obstructive pulmonary disease.

Patients avoid shortness of breath by becoming less active, leading to de-conditioning/ breathlessness downward spiral

Figure adapted from Reardon JZ. Am J Med 2006.[2]

[1]ZuWallack R. COPD 2007;

[2] Reardon JZ. Am J Med 2006

Case Study

- 67-year-old male; 20 cigarettes a day for 40 years
- Diagnosed with COPD after complaining of breathlessness during routine activities such as walking; “smokers cough in the mornings”
- Pre-bronchodilator spirometry: FEV_1 = 1.60 L, FVC = 2.60 L, FEV_1 % predicted = 60%; CAT score 28
- Post-bronchodilator: FEV_1 = 1.64 L, FVC = 2.65 L, FEV_1 % predicted = 63%

- Prescribed tiotropium once daily
  - FEV_1 increased to 1.68 L; CAT score 24 after 8 weeks

- Prescribed tiotropium/olodaterol
  - FEV_1 increased to 1.71 L; CAT score 22

- **What next?**

FEV_1, forced expiratory volume in 1 second; FVC, forced vital capacity; CAT, COPD Assessment Test

COPD Maintenance Treatments

- Long-acting beta agonists (LABA)
- Long-acting anti-muscarinics (LAMA)
- Inhaled corticosteroids (ICS)
- Oral PDE4 inhibitors

GOLD guideline recommendations for COPD maintenance therapy in symptomatic patients

- GOLD B: symptomatic, low exacerbation risk
  - Long-acting bronchodilator ➔ 2 long-acting bronchodilators
- GOLD D: symptomatic, high exacerbation risk
  - 2 long-acting bronchodilators ➔ add anti inflammatory ➔ add PDE4i, macrolide antibiotic

A high proportion of patients on LAMA are symptomatic; after moving to LAMA/LABA, many are still symptomatic

BLAZE study:

- **76% of LAMA (tio) pts did not achieve clinically meaningful improvement in breathlessness[1]**
- **64% of LAMA/LABA pts still did not achieve this improvement**



1. Mahler et al. Eur Respir J 2013

Limited/no benefit in terms of symptoms with ICS/LAMA/LABA vs LAMA/LABA

IMPACT (FF/UMEC/VI vs UMEC/VI)

- % of patients with ≥1 point improvement in breathlessness score (TDI)
  - 36% in the triple therapy group
  - 30% in the umeclidinium/vilanterol group (P<0.001)

TRIBUTE (BDP/FF/G vs IND/GLY)

- Rescue medication was not significantly different
- BDP/FF/G group had significantly greater improvement from baseline in E-RS score over the first 12 weeks, but not after

KRONOS (BGF vs GFF)

- No significant difference in TDI
- Only “nominally significant” improvements in change from baseline in E-RS score over 24 weeks
- Only “nominally significant” improvements in health status (SGRQ)

BDP; beclomethasone dipropionate; BGF, budesonide/glycopyrrolate/formoterol fumarate; E-RS, EXACT-Respiratory Symptoms; FF, fluticasone furoate; G/GLY, glycopyrronium; GFF, glycopyrrolate/formoterol fumarate; IND, indacaterol; SGRQ, St George’s Respiratory Questionnaire; UMEC; umeclidinium; VI, vilanterol

Lipson et al. N Engl J Med 2018;
Papi et al. Lancet 2018;
Ferguson et al. Lancet Respir Med 2018

Unmet needs in COPD

- Symptoms
- Impaired physical activity, airflow limitation
- Recurrent exacerbations
- Difficulty with handheld inhalers

COPD Maintenance Treatments

- Long-acting beta agonists (LABA)
- Long-acting anti-muscarinics (LAMA)
- Inhaled corticosteroids (ICS)
- Oral PDE4 inhibitors

Physical activity reduces with increasing COPD severity, which may lead to hospitalizations or death

Steps per day reduce with worsening lung function[1]



Decreasing activity levels reduce time to hospitalization and death[2]





CB, chronic bronchitis;
GOLD, Global initiative for chronic Obstructive Lung Disease

1. Adapted from Watz H. Eur Respir J 2009;
2. Garcia-Aymerich J, et al. Thorax. 2006;61:772-778

Effect on lung function: incremental benefits with LAMA and LAMA/LABA

LAMA and LABA alone vs placebo: trough FEV_1[1]



LAMA/LABA vs LAMA alone[2]



1. Kew et al. Cochrane Review 2014.
2. Han et al. npj Primary Care Respiratory Medicine 2018

Effect on quality of life: incremental benefits with single bronchodilators and LAMA/LABA

LAMA and LABA alone vs placebo: quality of life (SGRQ)[1]



← Improvement

LAMA/LABA vs LAMA alone: quality of life (SGRQ)[2]



← Improvement

1. Kew et al. Cochrane Review 2014.
2. Han et al. npj Primary Care Respiratory Medicine 2018

Unmet needs in COPD

- Symptoms
- Impaired physical activity, airflow limitation
- Recurrent exacerbations
- Difficulty with handheld inhalers

COPD Maintenance Treatments

- Long-acting beta agonists (LABA)
- Long-acting anti-muscarinics (LAMA)
- Inhaled corticosteroids (ICS)
- Oral PDE4 inhibitors

Mortality increases with the frequency of severe exacerbations



Soler-Cataluna JJ et al. Thorax. 60:925-931, 2005.

Repeated exacerbations reduce QoL



- 6-month prospective study after one exacerbation treated with antibiotics
- 31% had recurrent exacerbation
- N = patients remaining in the study at time point

With a further exacerbation

No new exacerbation

Spencer S. et al. *Thorax* 2003;58:589

After LAMA/LABA, move to LAMA/LABA/ICS (triple therapy)



ICS = inhaled corticosteroids;
LABA = long-acting β_2-agonist;
LAMA = long-acting muscarinic antagonist.

Efficacy of triple therapy on exacerbations is limited



Lipson DA et al. N Engl J Med 2018;378:1671-1680.

Effect of PDE-4 inhibitors on COPD management goals

- Statistically significant improvements in lung function; however, change was below what is usually considered a minimum clinically important difference
- Effect on COPD symptoms was small, regardless of how measured
- Individuals were 22% less likely to have an exacerbation; overall rate of exacerbations was reduced by 13%

Chong J et al. Cochrane Database of Systematic Reviews 2017

Roflumilast: effect on exacerbations mainly driven by patients with prior hospitalization



Proportion of patients with at least one COPD exacerbation using a log binomial regression, ITT

Martinez ATS 2015

Safety of Medications for the Prevention of COPD Exacerbations

- ICS
  - Pneumonia
  - Bones, Skin, Eyes
- Roflumilast
  - Nausea, Diarrhea, Weight Loss

Unmet needs in COPD

- Symptoms
- Impaired physical activity, airflow limitation
- Recurrent exacerbations
- Difficulty with handheld inhalers

COPD Maintenance Treatments

- Long-acting beta agonists (LABA)
- Long-acting anti-muscarinics (LAMA)
- Inhaled corticosteroids (ICS)
- Oral PDE4 inhibitors

Potential Reasons for Using Nebulized Medications in COPD

- Critical errors using conventional Inhalers in spite of adequate training
  - Inadequate inspiratory flow
  - Poor inspiratory timing
  - Inability to activate inhaler (by breath or by hand)
- Medical conditions limiting inhaler use
  - Mental impairment or cognitive dysfunction
  - Neuromuscular diseases
  - Arthritis
  - Visual impairment
- Inhaler device handling errors are common:
  - ~15–40% among elderly patients in primary care[1]
  - 81-85% in hospitalized patients[2]

1. Molimard M et al. *J Aerosol Med.* 2003;16:249-254.;
2. Press VG, et al. J Gen Intern Med. 2011;26(6):635-642.

Nebulized formulations are often prescribed for moderate-severe patients

- Current allocation nebulized therapy by COPD severity
  - Mild: 14%
  - Moderate: 27%
  - Severe: 37%

- Physicians also indicate a roughly even split between prescription of nebulized treatments for chronic use (54% patients) vs. temporary use post-discharge (46%)

IQVIA | Verona | COPD Maintenance Quantitative Study | Final Report | May 2018

What do we need?

- Additional options to control symptoms in treated patients
- An inhaled bronchodilator that has bronchodilating efficacy in COPD patients already on maintenance therapy
- An inhaled bronchodilator that can be delivered by nebulizer suitable for all COPD patients

Verona Pharma

Clinical Expert Perspectives

COPD Treatment Pipeline including RPL554

Gerard J Criner, MD

Professor and Founding Chair, Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University – Philadelphia, Pa

Airways Obstruction in COPD: Targets for Treatment



Barnes, Nat Rev, 2015

Airways Obstruction in COPD: Targets for Treatment



Major Goals for COPD Treatments

- Symptoms
- Impaired physical activity, airflow limitation
- Recurrent exacerbations
- Improve Survival

Barnes, Nat Rev, 2015

Multiple Agents are in Early Stages of Clinical Development as Potential Anti-Inflammatory Treatments for COPD



Barnes, Nat Rev, 2015

Overview of Maintenance Therapy for COPD

Category	Class	Symptoms	Exacerbation prevention
Bronchodilators	Long-acting β_2-agonists (LABAs)	++++	++
	Long-acting muscarinic antagonists (LAMAs)		
	LAMA/LABA		
Bronchodilator/ anti-inflammatory combinations	LABA/inhaled corticosteroids (LABA/ICS)	++++	++++
	LAMA/LABA/ICS		
Anti-inflammatories	ICS alone	++	++++
	PDE-4 inhibitors		
	Targeted anti-inflammatories		
Other	Smoking cessation	++	+++
	Mucolytics	++	+
	Vaccinations	+	+++
	Non-pharmacological devices	NA	NA

Compelling Need For Therapy with New Mode of Action for COPD

…but few such drugs in development for COPD



Includes NMEs in development for maintenance COPD only (excludes generic forms and reformulations / device combinations of existing compounds

Source: EvaluatePharma and STRH market intelligence

Bronchodilators in Development for COPD



Mode of Delivery
- Oral
- Inhalation
- Injectable

Includes NMEs in development for maintenance COPD only (excludes generic forms and reformulations / device combinations of existing compounds

Source: EvaluatePharma and STRH market intelligence

COPD Exacerbations in the Phase 3 Revefenacin Clinical Trial Program

Donohue ERS 2018

- Pooled data analysis showed nominally reduced COPD exacerbation burden by 15%–18% vs. placebo.
- Absence of selection for exacerbation-prone patients, small sample sizes, and lack of statistical power must be considered when interpreting results.

Table. COPD exacerbations

	Studies 0126 and 0127 (N = 1229)		
Endpoint measure	**Placebo (N = 418)**	**REV 88 µg/day (N = 417)**	**REV 175 µg/day (N = 395)**
All AECOPD LS mean annual rate (SE)	0.55 (0.08)	0.45 (0.07)	0.47 (0.07)
Relative risk (95% CI)		0.82 (0.54, 1.24)	0.85 (0.56, 1.28)
P value versus placebo		0.3505	0.4363

Inhaled Long-acting Dual Muscarinic Antagonist/β_2-adrenoceptor Agonist (MABA) for COPD/Asthma

- Dual-pharmacology muscarinic antagonist/ β_2-agonist (MABA) molecule is an exciting new approach to combine two mechanisms in a single entity
- May have additive or synergistic bronchodilation over either agent alone

Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients (***Psallidas ERS, 2018)***

- Trough FEV_1 mean difference vs placebo (Day 15):
  - 161 mL (100µg) and 260 mL (600µg)
- Substantial improvements vs placebo in breathlessness, cough and sputum scale (Day 14):
  - LS mean =-1.162
- Rescue medication use improved versus placebo for 600µg ($p<0.001$) and 100µg ($p=0.012$)

Anti-inflammatories in Development for COPD



Includes NMEs in development for maintenance COPD only (excludes generic forms and reformulations / device combinations of existing compounds

Source: EvaluatePharma and STRH market intelligence

Anti-IL-5 Therapy in COPD

IL- 5 Targets



Mepolizumab



Benralizumab

- Phase III trials GALATHEA and TERRANOVA assessed safety and efficacy as an add-on to dual or triple inhaled therapy vs placebo in patients with moderate-very severe COPD and history of exacerbations across a range of baseline blood eosinophils
  - **Both failed to meet primary outcome**

Dupilumab: IL-4/IL-13 Antagonist





Castro NEJM, 2018
Rabe, NEJM, 2018

Dupilumab: IL-4/IL-13 Antagonist



A phase III Trial is planned for COPD

A Dupilumab, 200 mg Every 2 Wk, vs. Matched Placebo

Subgroup	No. of Patients		Relative Risk vs. Placebo (95% CI)
	Placebo	Dupilumab	
Overall	317	631	0.52 (0.41–0.66)
Eosinophil count			
≥300 cells/mm³	148	264	0.34 (0.24–0.48)
≥150 to <300 cells/mm³	84	173	0.64 (0.41–1.02)
<150 cells/mm³	85	193	0.93 (0.58–1.47)
F_{ENO}			
≥50 ppb	71	119	0.31 (0.18–0.52)
≥25 to <50 ppb	91	180	0.39 (0.24–0.62)
<25 ppb	149	325	0.75 (0.54–1.05)



A Percentage Reduction in Oral Glucocorticoid Dose



No. of Patients							
Placebo	107	107	107	107	107	107	106
Dupilumab	103	103	102	101	101	101	101

Castro NEJM, 2018
Rabe, NEJM, 2018

Dupilumab: IL-4/IL-13 Antagonist



A phase III Trial is planned for COPD



A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) (IL-13) has been completed by Roche but results not published

Castro NEJM, 2018
Rabe, NEJM, 2018

Targeting Neutrophilic Disease: CXCR2 Antagonist

- CXCR2 is expressed on neutrophils and other cell types[1]
- Implicated in neutrophil recruitment, migration, activation, and goblet cell hyperplasia leading to pulmonary damage
- Receptor for IL-8



CXCR2 Antagonist MK-7123: Exacerbations



CXCR=C-X-C chemokine receptor; IL=interleukin.
Adapted from Gernez Y, et al. *Eur Respir J*. 2010;35(3):467-469.

Rennard AJRCCM, 2015

Targeting Neutrophilic Disease: CXCR2 Antagonist

- CXCR2 is expressed on neutrophils and other cell types[1]

Danirixin (GSK1325756) is a selective CXCR2 antagonist being developed as a potential anti-inflammatory agent for the treatment of COPD and influenza (NCT03170232)



CXCR2 Antagonist MK-7123: Exacerbations



CXCR=C-X-C chemokine receptor; IL=interleukin.
Adapted from Gernez Y, et al. *Eur Respir J*. 2010;35(3):467-469.

Rennard AJRCCM, 2015

p38 MAP Kinase Inhibitor Therapy in COPD

- MEREO conducted a Phase 2 trial double-blind, randomized, placebo-controlled study investigating BCT-197 (ACUMAPIMOD), on top of Standard of Care, for the treatment of patients with AECOPD.
  - Statistically significant reduction > 50% ($p \leq 0.027$ to 0.05) in number of clinical treatment failures, as measured by the number of rehospitalizations for the treatment of COPD at days 90 through 150.
- GSK performed a study of Losmapimod in 602 patients, it did not improve exercise tolerance or lung function, despite being well tolerated
- AZ recently reported at ERS 2018 that AZD7624 had a greater effect than budesonide on cytokine production from BECs
- Nemiralisib (GSK) in development as an anti-inflammatory drug for the treatment of inflammatory airways disease in patients with history of moderate or severe exacerbation of COPD[1]
  - Primary Outcome: trough FEV_1
  - Secondary Outcome: rate of moderate and severe exacerbations

1. Clinicaltrials.gov

Other Anti-inflammatory Therapies

- Low dose theophylline as add on to ICS to prevent exacerbations (TWICS study)
- SK2269557is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor being developed as an anti-inflammatory agent for COPD
- A novel potent inhaled inhibitor of neutrophil elastase -safety, tolerability and pharmacokinetics of single and repeat doses in 72 healthy males (NCT03056326); trial is in phase 1.
- A pilot study to explore safety of the antioxidant and metal chelator, Emeramide, (N1,N3-bis(2-mercaptoethyl) isophthalamide,) in COPD patients. The primary outcome is safety and tolerability. (NCT03123692)

Only One Dual Bronchodilator/Anti-inflammatory in Development for COPD



Includes NMEs in development for maintenance COPD only (excludes generic forms and reformulations / device combinations of existing compounds

Source: EvaluatePharma and STRH market intelligence

Mode of Delivery
- Oral
- Inhalation
- Injectable

RPL554: Promising Phase 2b Results Presented at ERS 2018

- Verona Pharma plc announces it will present an expanded dataset from its Phase 2b study evaluating RPL554 as a maintenance treatment for COPD at the European Respiratory Society International Congress in Paris, September 2018
- RPL554:
  - First-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4
  - Designed to have bronchodilator as well as anti-inflammatory properties
  - Currently in development for the maintenance treatment of COPD and for the treatment of cystic fibrosis

Verona press release 12 September 2018 http://www.veronapharma.com/blog/verona-pharma-to-present-expanded-dataset-from-rpl554-phase-2b-clinical-trial-in-copd-at-european-respiratory-society-internatio/

Summary

- Established/pipeline treatments for COPD are either bronchodilators, anti-inflammatory or combinations of these
  - No single molecule with both properties
- Several monoclonal antibody anti-inflammatory treatments in development
  - Generally targeting more severe patients/exacerbations
  - Likely to be costly
  - Some show efficacy in selected patient subgroups
- Small molecule and other anti-inflammatories have mixed results and are still at early stage
- RPL554 has unique dual bronchodilator/anti-inflammatory profile
  - MOA suggests potential to improve lung function, symptoms, and exacerbations

Clinical Expert Perspectives

RPL554 Clinical Results/ Ongoing trials

Dave Singh

M.D., Professor of clinical pharmacology and respiratory medicine, Medicines Evaluation Unit, University of Manchester & Manchester University NHS Foundation Trust, UK

Disclosures

- DS has received sponsorship to attend and speak at international meetings, honoraria for lecturing or attending advisory boards from the following pharmaceutical companies: Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Skypharma, Teva, Theravance and Verona.

Introduction

- Characteristic features of COPD are:[1]
  - Airflow obstruction
  - Persistent inflammation
- Many patients receiving current pharmacological treatments still suffer from:
  - Daily symptoms[2–4]
  - Exacerbations[5–7]
  - Accelerated lung function decline[8]

1. GOLD 2018; 2. Punekar et al. Pulm Ther 2016;2:59–72; 3. Kessler et al. Eur Respir J 2011;37:264–72; 4. Gruenberger et al. Int J Chron Obstruct Pulmon Dis 2017;12:937–44; 5. Thomas et al. COPD 2014;11:300–9; 6. Punekar et al. Int J Chron Obstruct Pulmon Dis 2014;9:65–73; 7. Dhamane et al. Int J Chron Obstruct Pulmon Dis 2015;10:2609–18; 8. Tashkin et al. New Engl J Med 2008;359:1543–54.

RPL554 First-in-Class Candidate: Bronchodilator and Anti-inflammatory in a Single Compound

RPL554: Dual **PDE3** and **PDE4** enzyme inhibitor

Impacts 3 Key Mechanisms in Respiratory Disease:

Mediated by:

RPL554 →

Airway Smooth Muscle Constriction	Inflammation	Mucus Hypersecretion
PDE3, PDE4	Neutrophils **PDE4**; Epithelial cells PDE3, **PDE4**; Macrophages PDE3, **PDE4**; Eosinophils **PDE4**; Lymphocytes PDE3, **PDE4**; Fibroblasts **PDE4**	PDE3, **PDE4**
Relaxation ↓	Anti-inflammatory Effects ↓	CFTR Activation ↓
Bronchodilation	**Reduced Inflammation**	**Increased Mucociliary Clearance**

Nebulized RPL554: Effective and Well Tolerated in 12 Clinical Trials with >730 Subjects

Recent trials:

Trial	Program	# of Subjects	Duration	Status
Phase 1/2	SAD MAD study with new suspension formulation	**112**	Single dose and twice daily for 5 days	Completed Sept 2015
Phase 2a	Dose ranging in asthma	**29**	Single dose	Completed March 2016
Phase 2a	Add-on to each of albuterol or ipratropium	**30**	Single dose	Completed May 2016
Phase 2a	Add-on to tiotropium (Spiriva®)	**30**	Dosed twice-daily for three days	Completed Sept 2017
Phase 1	Pharmacokinetic trial, US FDA new IND	**12**	Single dose	Completed Sept 2017
Phase 2b	Maintenance treatment	**403**	Dosed twice daily for four weeks	Completed March 2018
Phase 2	Add-on to dual bronchodilator therapy (LAMA/LABA: Stiolto)	**~75**	Dose twice daily for three days	Started July 2018

Nebulized RPL554: Effective and Well Tolerated in 12 Clinical Trials with >730 Subjects

Recent trials:

Trial	Program	# of Subjects	Duration	Status
Phase 1/2	SAD MAD study with new suspension formulation	**112**	Single dose and twice daily for 5 days	Completed Sept 2015
Phase 2a	Dose ranging in asthma	**29**	Single dose	Completed March 2016
Phase 2a	Add-on to each of albuterol or ipratropium	**30**	Single dose	Completed May 2016
Phase 2a	Add-on to tiotropium (Spiriva®)	**30**	Dosed twice-daily for three days	Completed Sept 2017
Phase 1	Pharmacokinetic trial, US FDA new IND	**12**	Single dose	Completed Sept 2017
Phase 2b	Maintenance treatment	**403**	Dosed twice daily for four weeks	Completed March 2018
Phase 2	Add-on to dual bronchodilator therapy (LAMA/LABA: Stiolto)	**~75**	Dose twice daily for three days	Started July 2018

RPL554 improved several measures of lung function over short-acting bronchodilators alone



*in completed clinical trials

Add-on RPL554 6 mg caused a significantly greater increase in peak and average (0-8h) FEV_1 compared with both ipratropium and salbutamol alone





**p<0.01

Singh et al. Eur Respir J 2018 (accepted for publication)

Nebulized RPL554: Effective and Well Tolerated in 12 Clinical Trials with >730 Subjects

Recent trials:

Trial	Program	# of Subjects	Duration	Status
Phase 1/2	SAD MAD study with new suspension formulation	**112**	Single dose and twice daily for 5 days	Completed Sept 2015
Phase 2a	Dose ranging in asthma	**29**	Single dose	Completed March 2016
Phase 2a	Add-on to each of albuterol or ipratropium	**30**	Single dose	Completed May 2016
Phase 2a	Add-on to tiotropium (Spiriva®)	30	Dosed twice-daily for three days	Completed Sept 2017
Phase 1	Pharmacokinetic trial, US FDA new IND	**12**	Single dose	Completed Sept 2017
Phase 2b	Maintenance treatment	**403**	Dosed twice daily for four weeks	Completed March 2018
Phase 2	Add-on to dual bronchodilator therapy (LAMA/LABA: Stiolto)	**~75**	Dose twice daily for three days	Started July 2018

RPL554 demonstrated additive bronchodilation when added to the LAMA tiotropium



** p<0.01
LAMA, long-acting muscarinic antagonist

Singh et al. Eur Respir J 2018 (accepted for publication)

RPL554: fast onset of action and significant reduction in hyperinflation (air-trapping) vs the LAMA tiotropium alone

Median Time to Onset on day 3
(≥ 10% improvement in FEV,; mins)

N = 27-28



Reduction in Hyperinflation (ml) on Day 2

N = 27-28



- Rapid onset of action
- Reduction in hyperinflation
- Well tolerated

Singh et al. Eur Respir J 2018 (accepted for publication)

RPL554: Broad Anti-Inflammatory Activity

- Significantly lower absolute number of neutrophils in sputum
  - A critical inflammatory cell in COPD
- Inhaled corticosteroids have no effect on neutrophils

RPL554 (n=21)
Placebo (n=21)







Source: Study VRP 120120, P1 clinical trial; n = 21 healthy subjects; May 2013
* p=0.002
** p=0.001
*** p=0.044





Nebulized RPL554: Effective and Well Tolerated in 12 Clinical Trials with >730 Subjects

Recent trials:

Trial	Program	# of Subjects	Duration	Status
Phase 1/2	SAD MAD study with new suspension formulation	**112**	Single dose and twice daily for 5 days	Completed Sept 2015
Phase 2a	Dose ranging in asthma	**29**	Single dose	Completed March 2016
Phase 2a	Add-on to each of albuterol or ipratropium	**30**	Single dose	Completed May 2016
Phase 2a	Add-on to tiotropium (Spiriva®)	**30**	Dosed twice-daily for three days	Completed Sept 2017
Phase 1	Pharmacokinetic trial, US FDA new IND	**12**	Single dose	Completed Sept 2017
Phase 2b	Maintenance treatment	**403**	Dosed twice daily for four weeks	Completed March 2018
Phase 2	Add-on to dual bronchodilator therapy (LAMA/LABA: Stiolto)	**~75**	Dose twice daily for three days	Started July 2018

Study overview

- **Description**
  - Phase IIb randomised, double blind, placebo controlled, dose ranging
- **Patient Population**
  - 403 patients with moderate-to-severe COPD, diagnosed >12 months previously
  - Males and females, age 40–75 years
- **Location**
  - Approximately 45 outpatient centres in Western and Eastern Europe
- **Background therapy**
  - No background bronchodilator therapy
  - Stable ICS regimen could be maintained

Study objectives

- **Primary**
  - RPL554 vs placebo on change from baseline in peak FEV_1 over 4 weeks

- **Secondary included**
  - Other FEV_1 measurements over 4 weeks
  - COPD symptoms (E-RS from EXACT-PRO)
  - St George's Respiratory Questionnaire for COPD (SGRQ-C)
  - Safety

E-RS, EXAcerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms
EXACT-PRO, Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome

Study design



BID, twice daily

Demographics

Parameter	Patients (N=403)
Age	63.2 years
Gender, male	60.5%
Race, Caucasian	100%
Disease characteristics	
COPD duration	7.8 years
Chronic bronchitis	62%
MRC ≥2	93.6%
Smoking, current smoker	54.8%
Pack-years	42.1
Screening spirometry	
FEV_1, post-salbutamol	55.8% predicted normal
FEV_1, post-salbutamol	1.64 L
FEV_1 reversibility	11.7%

MRC, Medical Research Council dyspnoea scale; FEV_1, forced expiratory volume in 1 second.

Lung function: 12-hour serial FEV_1 (Day 1)



FEV_1, forced expiratory volume in 1 second. Data are LS mean.

Lung function: Highly reproducible peak FEV_1 vs placebo over 4 weeks



FEV_1, forced expiratory volume in 1 second.
All treatment–placebo differences p<0.001. Data are LS mean and 95% confidence intervals.

Lung function: Significant improvement in FEV_1 over 0–12 h after 4 weeks vs placebo



FEV_1, forced expiratory volume in 1 second. Treatment–placebo difference: *p<0.05; †p<0.01; ‡p<0.001. Data are LS mean and 95% confidence intervals.

Lung function: Peak FEV_1 after 4 weeks



FEV_1, forced expiratory volume in 1 second. Reversible defined as FEV_1 change from pre- to post-salbutamol ≥12% and ≥200 mL; not reversible <12% or <200 mL. Treatment–placebo difference: *p<0.05; †p<0.01; ‡p<0.001. Data are LS mean and 95% confidence intervals.

Lung function: Trough FEV_1 after 4 weeks



FEV_1, forced expiratory volume in 1 second. Reversible defined as FEV_1 change from pre- to post-salbutamol ≥12% and ≥200 mL; not reversible <12% or <200 mL. Treatment–placebo difference: *p<0.05; †p<0.01. Data are LS mean and 95% confidence intervals.

Respiratory symptoms (E-RS): Progressive improvement over 4 weeks



MCID, minimum clinically important difference; E-RS, EXAcerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms.
Treatment–placebo difference: *p<0.05; †p<0.01; ‡p≤0.001. Data are LS mean and 95% confidence intervals.

Respiratory symptoms (E-RS): Improvement in all domains at Week 4



E-RS, EXAcerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms. Treatment–placebo difference: *p<0.05; †p<0.01. Data are LS mean and 95% confidence intervals.

Respiratory symptoms (E-RS): Improvement seen in reversible and non-reversible patients



MCID, minimum clinically important difference; E-RS, EXAcerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms

Health status (SGRQ-C) at Week 4



SGRQ-C, St George's Respiratory Questionnaire – COPD. Treatment–placebo difference: †p<0.01.

Adverse event profile generally similar to placebo

Patients, n (%)	RPL554				Placebo
	0.75 mg (N=81)	1.5 mg (N=81)	3 mg (N=82)	6 mg (N=80)	(N=79)
Any AE	27 (33.3)	36 (44.4)	29 (35.4)	29 (36.3)	31 (39.2)
Drug-related	8 (9.9)	11 (13.6)	12 (14.6)	8 (10.0)	10 (12.7)
Severe AE	4 (4.9)	1 (1.2)	2 (2.4)	1 (1.3)	2 (2.5)
Serious AE	2 (2.5)	2 (2.5)	1 (1.2)	1 (1.3)	1 (1.3)
Drug-related	1 (1.2)	1 (1.2)	0	0	0
AE leading to death	0	1 (1.2)	0	1 (1.3)	0

AE, adverse event.

Conclusions

- RPL554 – first-in-class, dual PDE3/4 inhibitor
- In patients with COPD, 4 weeks treatment with RPL554:
  - improved lung function
  - reduced symptoms
- The improvement in symptoms was progressive and clinically meaningful
  - Probably due to an anti-inflammatory effect
- RPL554 was well tolerated, all doses having a placebo-like adverse event profile

Nebulized RPL554: Effective and Well Tolerated in 12 Clinical Trials with >730 Subjects

Recent trials:

Trial	Program	# of Subjects	Duration	Status
Phase 1/2	SAD MAD study with new suspension formulation	**112**	Single dose and twice daily for 5 days	Completed Sept 2015
Phase 2a	Dose ranging in asthma	**29**	Single dose	Completed March 2016
Phase 2a	Add-on to each of albuterol or ipratropium	**30**	Single dose	Completed May 2016
Phase 2a	Add-on to tiotropium (Spiriva®)	**30**	Dosed twice-daily for three days	Completed Sept 2017
Phase 1	Pharmacokinetic trial, US FDA new IND	**12**	Single dose	Completed Sept 2017
Phase 2b	Maintenance treatment	**403**	Dosed twice daily for four weeks	Completed March 2018
Phase 2	Add-on to dual bronchodilator therapy (LAMA/LABA: Stiolto)	**~75**	Dose twice daily for three days	Started July 2018

Evaluating RPL554 as Add-on to Dual Bronchodilator Treatment in COPD Patients

Ongoing clinical study; ClinicalTrials.gov Identifier: NCT03673670; data expected 1Q19

Trial Description:

- Phase 2 randomized, double blind, placebo controlled, cross-over study
- Three day treatment with baseline to peak FEV1 on Day 3 as primary endpoint
- Assess nebulized RPL554 as add-on to LAMA/LABA treatment; some patients will maintain stable dose of ICS providing a triple background

Patient Population:

- About 75 moderate-to-severe COPD patients
- Males and females, age 40-75

Location:

- Centres in US and UK

RPL554 Dosage:

- Three arms, twice daily dosing with RPL554 at 1.5 mg and 6 mg or placebo

RPL554 in COPD: clinical summary

- Improves lung function when added to short-acting bronchodilators
- Improves lung function when added to long-acting tiotropium
- Provides significant, clinically meaningful bronchodilation up to 4 weeks vs placebo
  - Progressively improves symptoms
    - Reflects anti-inflammatory effect?
- Currently being investigated as add-on to dual bronchodilation

A new class of treatment in COPD: how could RPL554 alter the treatment paradigm?

- Many treated patients still require symptomatic improvement – there is room to do more
- RPL554 may provide a new anti-inflammatory option



Verona Pharma

Speaker Panel Q&A

Agenda

Verona Pharma

Time	Details
11:15 am – 11:30 am	**Welcome** (Jan-Anders Karlsson, CEO, Verona Pharma)
11:30 am – 12:00 pm	**The Patient Perspective, COPD Foundation** (*John Linnell, Patient; Sara Latham, COO, COPD Foundation*)
12:00 pm – 1:10 pm	**Clinical Expert Perspective** • *COPD treatment challenges/ unmet need [Bob Wise, M.D. 20 min]* • *COPD Treatment Pipeline inc. RPL554 [Gerard Criner, M.D. 20 min]* • *RPL554 Clinical Results/ Ongoing trials [Dave Singh, M.D. 30 min]*
1:10 pm – 1:45 pm	**Speaker Panel Q&A**
1:45 pm – 2:00 pm	**Close** (Jan-Anders Karlsson)

Verona Pharma

Summary & close

Jan-Anders Karlsson

CEO, Verona Pharma

RPL554 – A Promising Novel Treatment For Patients with COPD:

Verona Pharma

Data collected to date indicates:

- ✓ RPL554 – unique PDE3/4 inhibitor with bronchodilator and anti-inflammatory effects, and well tolerated
- ✓ Improves symptoms in moderate to severe, symptomatic COPD patients on twice daily dosing
- ✓ Effective both as stand-alone drug and as add-on to standard COPD treatments
- ✓ Planning FDA End of phase 2 meeting 2H 2019
- ✓ Subsequently, advancing nebulized RPL554 into Phase 3 trials in uncontrolled and symptomatic patients despite using standard COPD medications